from Yahoo Finance https://ift.tt/39oqGDL

There wouldn't be many who think MarineMax, Inc.'s (NYSE:HZO) price-to-earnings (or "P/E") ratio of 15.1x is worth a…

from Yahoo Finance https://ift.tt/30JJBFc

MONTREAL and CHARLOTTE, N.C., July 23, 2020 /CNW/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has entered into a securities purchase agreement with affiliates of an existing shareholder, RTW Investments, LP, for a $25 million private placement. The private placement is expected to close on or about July 24, 2020, subject to the satisfaction of customary closing conditions. The Company is selling pre-funded warrants to acquire an aggregate 6,655,131 common shares for aggregate gross proceeds of $25 million, or a purchase price of $3.7465 per pre-funded warrant.

from Yahoo Finance https://ift.tt/2CvVh6F

As vaccine candidate company Novavax surges 3,161% in 2020, one analyst is sounding the alarm on what he calls a ridiculous amount of speculation.

from Yahoo Finance https://ift.tt/3jF1AFN

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made…

from Yahoo Finance https://ift.tt/32ZtYfV

AT&T said sales for the second quarter of 2020 were lower across all of its segments because of the coronavirus pandemic. That included a 22.9% plunge in WarnerMedia revenue, which the telco said was partly due to lower content and ad sales related to COVID-19. WarnerMedia's Q2 2020 operating revenue was $6.8 billion, down 22.9% […]

from Yahoo Finance https://ift.tt/2CXx9JR

from Yahoo Finance https://ift.tt/3eR0tPl

While air travel had picked up over the past two months from pandemic-driven lows in April, demand has started slowing again as coronavirus cases surge across the United States and states re-impose quarantine restrictions. It reported a net loss of $2.07 billion, or $4.82 per share, for the quarter ended June 30, compared with a profit of $662 million, or $1.49 per share, a year earlier.

from Yahoo Finance https://ift.tt/3eXRLyN

MONTREAL and CHARLOTTE, N.C., July 23, 2020 /CNW/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced a clinical and regulatory update for its pivotal program with etripamil following recent interactions with the U.S. Food and Drug Administration (FDA). Etripamil nasal spray is the Company’s investigational novel short-acting calcium channel blocker for patients with paroxysmal supraventricular tachycardia (PSVT).

from Yahoo Finance https://ift.tt/2WNYFR8

from Yahoo Finance https://ift.tt/2CXd9XO